+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Critical Care Therapeutics: Global Strategic Business Report

  • PDF Icon

    Report

  • 242 Pages
  • December 2023
  • Region: Global
  • Global Industry Analysts, Inc
  • ID: 5140868

Quick Summary:

Emerging opportunities in the growing Critical Care Therapeutics market are clearly outlined in our latest market research report, giving you the insights needed to stay competitive while crafting your business strategy for the next decade. Providing an in-depth analysis of current trends and future projections, this report not only places the global market value at an estimated US$7.4 billion by 2030 but also emphasizes the role of key market segments like Albumin which is projected to record significant growth.

Detailed geographic analysis further emphasizes the potential in rapidly growing markets like China, along with a solid review of established markets such as the United States, Europe, Japan, and Canada. Highlighting the strategies and performances of prominent market players can provide a comprehensive understanding to drive your strategic planning. Moreover, the report offers timely updates on key market events and access to an online collaborative research platform, ensuring essential data and trends are always at your fingertips. This definitive Critical Care Therapeutics Market report is your ultimate guide to navigating the evolving landscape and identifying profitable pathways in this exciting sector.

Global Critical Care Therapeutics Market to Reach $7.4 Billion by 2030

The global market for Critical Care Therapeutics estimated at US$4.8 Billion in the year 2022, is projected to reach a revised size of US$7.4 Billion by 2030, growing at a CAGR of 5.6% over the analysis period 2022-2030. Albumin, one of the segments analyzed in the report, is projected to record 6.8% CAGR and reach US$3.7 Billion by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Prothrombin Complex Concentrates segment is readjusted to a revised 4.5% CAGR for the next 8-year period.

The U.S. Market is Estimated at $1.3 Billion, While China is Forecast to Grow at 9% CAGR

The Critical Care Therapeutics market in the U.S. is estimated at US$1.3 Billion in the year 2022. China, the world's second largest economy, is forecast to reach a projected market size of US$1.8 Billion by the year 2030 trailing a CAGR of 9% over the analysis period 2022 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 3.1% and 4.3% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately 3.9% CAGR.

Select Competitors (Total 37 Featured) -

  • Abeona Therapeutics Inc.
  • ADMA Biologics, Inc.
  • Albumedix Ltd.
  • Asklepios Biopharmaceutical, Inc.
  • Aspen Pharmacare Holdings Ltd.
  • Baxter International Inc.
  • Bayer Healthcare AG
  • Bio Products Laboratory Ltd.
  • BioDelivery Sciences International, Inc.
  • Biogen, Inc.
  • BioMarin Pharmaceutical Inc.
  • Biotest Pharmaceuticals Corporation
  • Bristol-Myers Squibb Company
  • Catalyst Biosciences, Inc.
  • China Biologic Products Holdings, Inc.
  • Cosmo Pharmaceuticals NV
  • CSL Behring
  • Grifols International SA
  • Kamada Ltd.
  • Kedrion Biopharma, Inc.
  • Medxbio Pte. Ltd.
  • Merck & Co., Inc.
  • Mitsubishi Tanabe Pharma Corporation
  • Novo Nordisk A/S
  • Novozymes A/S
  • Octapharma AG
  • Portola Pharmaceuticals, Inc.
  • ProMetic Life Sciences, Inc.
  • rEVO Biologics, Inc.
  • Rockwell Medical
  • Sanquin
  • Shanghai RAAS Blood Products Co., Ltd.
  • Shire PLC
  • Teva Pharmaceutical Industries Ltd.
  • The Medicines Company
  • Thermo Fisher Scientific, Inc.
  • Ventria Bioscience

What's New?

  • Special coverage on Russia-Ukraine war; global inflation; easing of zero-Covid policy in China and its `bumpy` reopening; supply chain disruptions, global trade tensions; and risk of recession.
  • Global competitiveness and key competitor percentage market shares
  • Market presence across multiple geographies - Strong/Active/Niche/Trivial
  • Online interactive peer-to-peer collaborative bespoke updates
  • Access to digital archives and Research Platform
  • Complimentary updates for one year
Frequently Asked Questions about the Global Market for Critical Care Therapeutics

What is the estimated value of the Global Market for Critical Care Therapeutics?

The Global Market for Critical Care Therapeutics was estimated to be valued at $4.8 Billion in 2022.

What is the growth rate of the Global Market for Critical Care Therapeutics?

The growth rate of the Global Market for Critical Care Therapeutics is 5.6%, with an estimated value of $7.4 Billion by 2030.

What is the forecasted size of the Global Market for Critical Care Therapeutics?

The Global Market for Critical Care Therapeutics is estimated to be worth $7.4 Billion by 2030.

Who are the key companies in the Global Market for Critical Care Therapeutics?

Key companies in the Global Market for Critical Care Therapeutics include Abeona Therapeutics Inc., ADMA Biologics, Inc., Albumedix Ltd., Asklepios Biopharmaceutical, Inc., Aspen Pharmacare Holdings Ltd., Baxter International Inc., Bayer Healthcare AG, Bio Products Laboratory Ltd., BioDelivery Sciences International, Inc. and Biogen, Inc..

Table of Contents

I. METHODOLOGYII. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
  • Influencer Market Insights
  • Critical Care Therapeutics - Global Key Competitors Percentage Market Share in 2022 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2022 (E)
  • Impact of Covid-19 and a Looming Global Recession
2. FOCUS ON SELECT PLAYERS3. MARKET TRENDS & DRIVERS
4. GLOBAL MARKET PERSPECTIVE
  • Table 1: World Recent Past, Current & Future Analysis for Critical Care Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
  • Table 2: World Historic Review for Critical Care Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 3: World 16-Year Perspective for Critical Care Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2023 & 2030
  • Table 4: World Recent Past, Current & Future Analysis for Albumin by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
  • Table 5: World Historic Review for Albumin by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 6: World 16-Year Perspective for Albumin by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030
  • Table 7: World Recent Past, Current & Future Analysis for Prothrombin Complex Concentrates by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
  • Table 8: World Historic Review for Prothrombin Complex Concentrates by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 9: World 16-Year Perspective for Prothrombin Complex Concentrates by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030
  • Table 10: World Recent Past, Current & Future Analysis for Antithrombin Concentrates by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
  • Table 11: World Historic Review for Antithrombin Concentrates by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 12: World 16-Year Perspective for Antithrombin Concentrates by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030
  • Table 13: World Recent Past, Current & Future Analysis for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
  • Table 14: World Historic Review for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 15: World 16-Year Perspective for Other Drug Classes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030
  • Table 16: World Recent Past, Current & Future Analysis for Deep Vein Thrombosis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
  • Table 17: World Historic Review for Deep Vein Thrombosis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 18: World 16-Year Perspective for Deep Vein Thrombosis by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030
  • Table 19: World Recent Past, Current & Future Analysis for Pulmonary Embolism (PE) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
  • Table 20: World Historic Review for Pulmonary Embolism (PE) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 21: World 16-Year Perspective for Pulmonary Embolism (PE) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030
  • Table 22: World Recent Past, Current & Future Analysis for Acute Coronary Syndrome by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
  • Table 23: World Historic Review for Acute Coronary Syndrome by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 24: World 16-Year Perspective for Acute Coronary Syndrome by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030
  • Table 25: World Recent Past, Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
  • Table 26: World Historic Review for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 27: World 16-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030
  • Table 28: World Critical Care Therapeutics Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
III. MARKET ANALYSIS
UNITED STATES
  • Critical Care Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2023 (E)
CANADA
JAPAN
  • Critical Care Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2023 (E)
CHINA
  • Critical Care Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2023 (E)
EUROPE
  • Critical Care Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2023 (E)
FRANCE
  • Critical Care Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2023 (E)
GERMANY
  • Critical Care Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2023 (E)
ITALY
UNITED KINGDOM
  • Critical Care Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2023 (E)
SPAINRUSSIAREST OF EUROPE
ASIA-PACIFIC
  • Critical Care Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2023 (E)
AUSTRALIA
  • Critical Care Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2023 (E)
INDIA
  • Critical Care Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2023 (E)
SOUTH KOREAREST OF ASIA-PACIFIC
LATIN AMERICA
  • Critical Care Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2023 (E)
ARGENTINABRAZILMEXICOREST OF LATIN AMERICA
MIDDLE EAST
  • Critical Care Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2023 (E)
IRANISRAELSAUDI ARABIAUNITED ARAB EMIRATESREST OF MIDDLE EAST
AFRICA
  • Critical Care Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2023 (E)
IV. COMPETITION

Companies Mentioned

A selection of companies mentioned in this report includes:

  • Abeona Therapeutics Inc.
  • ADMA Biologics, Inc.
  • Albumedix Ltd.
  • Asklepios Biopharmaceutical, Inc.
  • Aspen Pharmacare Holdings Ltd.
  • Baxter International Inc.
  • Bayer Healthcare AG
  • Bio Products Laboratory Ltd.
  • BioDelivery Sciences International, Inc.
  • Biogen, Inc.
  • BioMarin Pharmaceutical Inc.
  • Biotest Pharmaceuticals Corporation
  • Bristol-Myers Squibb Company
  • Catalyst Biosciences, Inc.
  • China Biologic Products Holdings, Inc.
  • Cosmo Pharmaceuticals NV
  • CSL Behring
  • Grifols International SA
  • Kamada Ltd.
  • Kedrion Biopharma, Inc.
  • Medxbio Pte. Ltd.
  • Merck & Co., Inc.
  • Mitsubishi Tanabe Pharma Corporation
  • Novo Nordisk A/S
  • Novozymes A/S
  • Octapharma AG
  • Portola Pharmaceuticals, Inc.
  • ProMetic Life Sciences, Inc.
  • rEVO Biologics, Inc.
  • Rockwell Medical
  • Sanquin
  • Shanghai RAAS Blood Products Co., Ltd.
  • Shire PLC
  • Teva Pharmaceutical Industries Ltd.
  • The Medicines Company
  • Thermo Fisher Scientific, Inc.
  • Ventria Bioscience